KSC
IDXG

Kendall Square Capital’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Kendall Square Capital’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,265
Closed -$2.54M – 43
2013
Q3 		$2.54M Sell
5,265
-1,396
-21% -$669K 1.88% 22
2013
Q2 		$3.13M Buy
+6,661
New +$3.02M 1.85% 27

Other funds holding IDXG

HA
Heartland Advisors Milwaukee, Wisconsin $2.25B AUM 44.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
PHS
Pekin Hardy Strauss Chicago, Illinois $1.14B AUM 37.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Kennedy Capital Management
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
LCM
Leonard Capital Management Vero Beach, Florida $5.25M AUM
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $126M AUM 15.32% 1-Year Est. Return

Kendall Square Capital's IDXG Position: Q4 2013 in Review

Kendall Square Capital sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q4 2013, closing a stake of 5,265 shares — an estimated $2.54M sold.

Kendall Square Capital first reported a position in IDXG in Q2 2013 and held it in 2 quarters. The position peaked at $3.13M in Q2 2013. 26 funds tracked by Wall St. Rank hold IDXG as of Q4 2013.

  • Kendall Square Capital reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q4 2013 after selling out during the quarter.
  • Kendall Square Capital sold 5,265 Interpace Biosciences, Inc. Common Stock shares in Q4 2013, an estimated $2.54M.
  • Kendall Square Capital first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Kendall Square Capital's Interpace Biosciences, Inc. Common Stock position peaked at $3.13M in Q2 2013.
  • 26 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q4 2013.

Based on Kendall Square Capital's 13F filing for Q4 2013, filed 14 Feb 2014.